| Project/Area Number |
10671493
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
TACHIBANA Masaaki Keio Univ., Dept.of Urology, Associate Professor, 医学部, 助教授 (70129526)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MURAI Masaru Keio Univ., Dept.of Urology, Professor, 医学部, 教授 (90101956)
ASAUKRA Hirotaka Keio Univ., Dept.of Urology, Assistant Professor, 医学部, 専任講師 (50175840)
NAKASHIMA Jun Keio Univ., Dept.of Urology, Assistant Professor, 医学部, 専任講師 (10167546)
|
|---|
| Project Period (FY) |
1998 – 1999
|
| Project Status |
Completed (Fiscal Year 1999)
|
| Budget Amount *help |
¥3,300,000 (Direct Cost: ¥3,300,000)
Fiscal Year 1999: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 1998: ¥2,600,000 (Direct Cost: ¥2,600,000)
|
|---|
| Keywords | cytokine-producing cancer cells / NF κ B / gene therapy / adenovirus / IKB |
|---|
| Research Abstract |
This study was designed to investigate cancer gene therapy against cytokine producing cells. Firstable, we succeeded establishment of cytokine producing human urological cancer cells including kidney (KU-19-20) and bladder (KU-19-19) as a target model. These cells have been shown to secrete a variety of cytokines such as granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), interleiukin-6 (IL-6) and IL-8. Then we investigated whether the cell growth and apoptosis of cytokine-producing cells can be regulated by nuclear factor kappa B (NFκB). When IκB stable form cDNA (which is known to be the NFκB inhibitor) was transfected into the cells with adenovirus vector, the production of several cytokines was significantly suppressed in these cells by the gene delivery. Notably, the significant induction of apoptosis was also observed by the gene therapy. These results suggest that NFκB activation maintains the cell viability as well as regulates cytokine production in cytokine-producing cancer cells and therefore these in vitro experiments support a rationale for preclinical in vivo studies to demonstrate growth inhibition in established tumors.
|
